HELSINKI, June 6 (Reuters) - Finnish drugs company Orion Corp. said results of a Phase II clinical study on the oral formulation of its levosimendan heart failure drug were not good enough to start Phase III studies. “The study results are not sufficient for starting Phase III clinical trials,” Orion said in a statement.
